Leuven, Belgium – February 28, 2024: LynxCare is excited to announce the appointment of Laurent van Lerberghe, former Chief Strategy Officer at Sanofi, as Investor and Board Advisor. LynxCare is a scale-up company in Clinical Artificial Intelligence part of the CB Insights Global Digital Health 150, supported by renowned VC investors MTIP (CH), Elaia (FR), B2Ventures (CH-DE) and Heran partners (BE).

This news not only confirms LynxCare’s robust positioning and notable achievements to date, but also marks a significant milestone as the company embarks on its next chapter focused on accelerating access of new medicines to the market and Real-World Evidence Generation powered by its AI technology to unlock siloed hospital data for research.

With 25 years of healthcare experience, Laurent van Lerberghe has a strong track record of leading and developing businesses globally. Over the last three years, Laurent served as Chief Strategy Officer at Sanofi, working closely with the CEO, and contributing significantly to the company's growth as one of the architects of multiple strategic acquisitions. He also expedited funding in oncology, genomic medicines, and digital health. Prior to Sanofi, Laurent held various high-level commercial positions at Abbott for a decade, in Europe, the US and Asia.

Earlier this year, Laurent embraced the role of Investor in Digital Health, focusing on accelerating digital health across Europe. In just 12 months, he has successfully completed initial investments in select European digital health companies, working closely together with entrepreneurs to help them develop their start-up and uphold their commitments to patients.

“We are excited to welcome Laurent as Investor and Board Advisor. His extensive experience, strategic vision and entrepreneur mindset will undoubtedly propel LynxCare to new heights.” – Georges De Feu, CEO & Co-Founder of LynxCare

"I'm thrilled to join as an Investor and work closely with LynxCare leadership to achieve its ambition. Access of new medicines to the market and Real-World Evidence generation are critical components of healthcare innovation. LynxCare’s AI enabled technology and relationships with hospitals have positioned it uniquely to improve access, enable monitoring of broader clinical biomarker and data sets, accelerate pharmaceutical innovation and adoption, ultimately improving patient outcomes. Using real life clinical data for research and access has long been a concept pharma was running after. LynxCare is making it a reality. Well-established across Belgium & the Netherlands with first proof points in France, it is now expanding across Europe and USA. With its unique AI capabilities and experienced clinical team, LynxCare is well-positioned to be a leader in this field" - Laurent van Lerberghe.